These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Spermicide condoms linked to latex allergy. AIDS Alert; 1996 Sep; 11(9):107-8. PubMed ID: 11363727 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of nonoxynol-9 questioned. Rep Med Guidel Outcomes Res; 2000 Aug; 11(16):5-6. PubMed ID: 11799994 [No Abstract] [Full Text] [Related]
7. The efficacy of nonoxynol-9 from an in vivo point of view. Wittkowski KM AIDS; 1997 Mar; 11(3):392-4. PubMed ID: 9147438 [No Abstract] [Full Text] [Related]
8. Over-the-counter vaginal contraceptive and spermicide drug products containing nonoxynol 9; required labeling. Final rule. Food and Drug Administration, HHS Fed Regist; 2007 Dec; 72(243):71769-85. PubMed ID: 18159651 [TBL] [Abstract][Full Text] [Related]
9. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Phillips DM; Sudol KM; Taylor CL; Guichard L; Elsen R; Maguire RA Contraception; 2004 Aug; 70(2):107-10. PubMed ID: 15288213 [TBL] [Abstract][Full Text] [Related]
10. Nonoxynol-9 does not protect against HIV. AIDS Patient Care STDS; 2008 Jan; 22(1):89-93. PubMed ID: 18442307 [No Abstract] [Full Text] [Related]
11. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. Van Damme L; Niruthisard S; Atisook R; Boer K; Dally L; Laga M; Lange JM; Karam M; Perriens JH AIDS; 1998 Mar; 12(4):433-7. PubMed ID: 9520174 [TBL] [Abstract][Full Text] [Related]
12. Microbicides. Raising new barriers against HIV infection. Trager RS Science; 2003 Jan; 299(5603):39. PubMed ID: 12511630 [No Abstract] [Full Text] [Related]
13. From the clinical effectiveness unit (CEU). The members' enquiry service: frequently asked questions. de Souza A; Brechin S; Penney G J Fam Plann Reprod Health Care; 2004 Jul; 30(3):190-1. PubMed ID: 15222932 [No Abstract] [Full Text] [Related]
14. Clinical microbicide research: an overview. Van Damme L Trop Med Int Health; 2004 Dec; 9(12):1290-6. PubMed ID: 15598260 [TBL] [Abstract][Full Text] [Related]
15. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893 [TBL] [Abstract][Full Text] [Related]
16. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Lederman MM; Offord RE; Hartley O Nat Rev Immunol; 2006 May; 6(5):371-82. PubMed ID: 16639430 [TBL] [Abstract][Full Text] [Related]
17. Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Amaral E; Perdigao A; Souza MH; Mauck C; Waller D; Zaneveld L; Faundes A Contraception; 2006 May; 73(5):542-7. PubMed ID: 16627043 [TBL] [Abstract][Full Text] [Related]
18. Factors affecting the reproducibility and validity of colposcopy for product development: review of current literature. Ballagh S J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S152-5. PubMed ID: 16419264 [TBL] [Abstract][Full Text] [Related]
19. Nonoxynol-9 ineffective in preventing HIV infection. Trop Doct; 2003 Apr; 33(2):127. PubMed ID: 12680562 [No Abstract] [Full Text] [Related]
20. Inhibiting sexual transmission of HIV-1 infection. Shattock RJ; Moore JP Nat Rev Microbiol; 2003 Oct; 1(1):25-34. PubMed ID: 15040177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]